Clinical trial readout dates for Crinetics Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 1/2 atumelnant Cushing Syndrome; Cushing Disease · NCT05804669 | August 2026 Primary data collected |
| Phase 3 Atumelnant Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia · NCT07144163 | May 2027 Recruiting |
| Phase 3 Paltusotine Carcinoid Syndrome; Carcinoid · NCT07087054 | August 2027 Ongoing |
| Phase 1/2 CRN09682 SST2-positive Neuroendocrine Neoplasms; Neuroendocrine Tumors · NCT07129252 | August 2027 Ongoing |
| Phase 2 atumelnant (CRN04894) Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia · NCT06712823 | July 2029 Recruiting |
| Phase 2/3 Atumelnant Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia · NCT07159841 | March 2030 Recruiting |